Zafgen's next-generation MetAP2 inhibitor well tolerated in Ph I

Zafgen Inc. (NASDAQ:ZFGN) said ZGN-1061 reduced subjects’ weight and was well tolerated with no serious adverse events reported in the 2-part Phase I ZAF-1061-101 trial in healthy volunteers and obese patients. Next half, the company plans to start a Phase II trial of the product in overweight or obese Type II diabetics. ZGN-1061 is a second-generation methionine aminopeptidase 2 (MetAP2) inhibitor.

The Phase I trial included a single ascending-dose portion in 39 healthy volunteers who received 0.2-4.8 mg subcutaneous ZGN-1061 and a multiple ascending-dose portion in 29 overweight or obese patients who received twice-weekly 0.2, 0.6 or 1.8 mg subcutaneous ZGN-1061 for 4 weeks...